Matthew B. Wright
About
In The Last Decade
Matthew B. Wright
52 papers receiving 1.4k citations
Peers
Comparison fields: 5 of 120
- Molecular Biology 790
- Sensory Systems 203
- Surgery 179
- Oncology 166
- Physiology 135
Countries citing papers authored by Matthew B. Wright
This map shows the geographic impact of Matthew B. Wright's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matthew B. Wright with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matthew B. Wright more than expected).
Fields of papers citing papers by Matthew B. Wright
This network shows the impact of papers produced by Matthew B. Wright. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matthew B. Wright. The network helps show where Matthew B. Wright may publish in the future.
Co-authorship network of co-authors of Matthew B. Wright
This figure shows the co-authorship network connecting the top 25 collaborators of Matthew B. Wright. A scholar is included among the top collaborators of Matthew B. Wright based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matthew B. Wright. Matthew B. Wright is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | 1 | |
| 2 | 15 | |
| 3 | 15 | |
| 4 | 33 | |
| 5 | 52 | |
| 6 | 43 | |
| 7 | The dual PPAR-α/γ agonist aleglitazar attenuates retinopathy in streptozotocin diabetic rats | 1 |
| 8 | 37 | |
| 9 | Recent progress in liver X receptor-selective modulators. | 9 |
| 10 | Abstract 10854: Aleglitazar, a Balanced Dual PPAR alpha/ gamma Agonist, Decreases Lipolysis and Cytokine Production in a Cellular Model of Inflamed Human Adipose Tissue. | 4 |
| 11 | 11 | |
| 12 | 11 | |
| 13 | 28 | |
| 14 | 43 | |
| 15 | 8 | |
| 16 | 9 | |
| 17 | 34 | |
| 18 | 41 | |
| 19 | 23 | |
| 20 | 64 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.